Please try another search
For the three months ended 31 March 2022, SCM LifeScience Co Ltd revenues increased 13% to W113.6M. Net loss decreased 22% to W5.7B. Revenues reflect cosmetics segment increase of 32% to W54.1M. Lower net loss reflects Stock-Based Compensation decrease of 98% to W27.5M (expense), R & D Expense decrease of 7% to W2.95B (expense). Basic Earnings per Share excluding Extraordinary Items increased from -W614.00 to -W474.34.
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Total Revenue | 224.81 | 284.57 | 88.81 | 97.51 |
Gross Profit | 159.91 | 49.75 | 41.94 | 64.56 |
Operating Income | -3171.69 | -3578.17 | -2874.13 | -3373.68 |
Net Income | -6898.48 | -6171.71 | -5290.58 | -5600.66 |
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Total Assets | 25403.79 | 32916.84 | 22223.18 | 26459.46 |
Total Liabilities | 4930.24 | 5279.89 | 7031.76 | 7009.34 |
Total Equity | 20473.54 | 27636.95 | 15191.43 | 19450.12 |
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | -3238.62 | -2904.51 | -2652.93 | -3339.96 |
Cash From Investing Activities | -7933.89 | -62.66 | 500.27 | 486.18 |
Cash From Financing Activities | -52.1 | 15886.96 | 783.81 | 106.73 |
Net Change in Cash | -11224.61 | 12919.79 | -1368.86 | -2747.05 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review